

NUROSENE APPOINTS SEASONED FINANCIAL EXECUTIVE GINO DEMICHELE TO BOARD OF DIRECTORS

TORONTO, April. 7, 2022 /CNW/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a healthtech company focused on delivering innovative AI derived technology solutions for mental performance and wellness, appoints Gino DeMichele to the Board of Directors.

"I am honoured to join an organization with a vision and solution that directly addresses the widespread issues of burnout, stress and mental wellness." said Mr. DeMichele.

Mr. DeMichele currently serves as the President and Chief Executive Officer of A2 Capital Management Inc., a private merchant banking and trading operation active since 2006. Prior to this, Mr. DeMichele was Vice President and Senior Investment Advisor at Various Canadian brokerage firms from 1994 to 2013. He has been engaged in global financial markets since 1992 and brings 30 years of finance, public and private equity, merger and acquisition expertise.

About Nurosene

Nurosene is a healthtech company focused on delivering innovative AI-based technology solutions that support mental performance and wellness. Our mission is to build healthier, more productive brains by leveraging our cutting-edge technology. Our world-renowned team and partners are disrupting traditional mental wellness treatments and are positioned at the forefront of critical research and innovations. Further, NetraMark, a wholly owned subsidiary of Nurosene Health Inc., provides proprietary next-generation AI solutions for pharmaceutical and biotechnology companies across the spectrum of disease.

For more information, visit www.nurosene.com.

Forward-Looking Statements


This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Specifically, this news release contains forward looking statements relating to, among others, activities of the Company's appointment of Mr. Gino DeMichele to the Board of Directors and the Company's future growth and expansion.

Any forward-looking information speaks only as of the date on which it is made, and, except as

required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene's Final Long Form Prospectus dated May 20, 2021 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene's Final Long Form Prospectus could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Nurosene Health Inc.

 View original content to download multimedia:
<http://www.newswire.ca/en/releases/archive/April2022/07/c5562.html>

%SEDAR: 00050449E

For further information: Blake Sing, Chief Financial Officer, investors@nurosene.com, (416) 859-8838

CO: Nurosene Health Inc.

CNW 09:00e 07-APR-22